teplizumab Report issue

Biologics mAb Approved FDA Breakthrough Therapy FDA Priority Review FDA

Active Ingredient History

  • Now
Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D.   Wikipedia

More Chemistry
anti-cd3 monoclonal antibody | hokt3gamma1 | hokt3 gamma 1 (ala-ala) | hokt3gamma1 (ala-ala) | hokt3gamma1(ala-ala) | hokt3γ1 | humanized okt3 gamma1(ala-ala) | humanized okt3gamma1(ala-ala) | humanzied okt3 | mga031 | okt3gamma1 ala-ala, humanized | teplizumab


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue